Introduction
============

Paclitaxel is a microtubule-stabilizing drug with significant activity in ovarian cancer ([@bib29]). Regimes containing weekly low-dose paclitaxel are highly effective ([@bib20]), even in tumors resistant to conventional three-weekly administration ([@bib28]; [@bib23]). Although paclitaxel can stabilize microtubules at nanomolar concentrations ([@bib19]), the cell cycle effects of low-dose exposure are complex and include mitotic slippage and catastrophic mitotic exit ([@bib33]).

Oncolytic viruses are a new class of anti-cancer treatment, based upon their ability to replicate selectively within malignant cells. The adenovirus *dl*922-947 harbors a 24-bp deletion in E1A CR2 and induces cell death selectively in cells with a defective Rb/G1-S checkpoint pathway ([@bib17]), a finding observed in over 90% human cancers ([@bib37]). Clinical trials of E1A CR2-deleted adenoviruses have commenced (<http://www.clinicaltrials.gov>; reference NCT00805376). E1A CR2 is important for binding to pRb, which releases E2F with the consequent transactivation of genes driving S-phase entry and cell cycle progression ([@bib13]). We have previously shown that *dl*922-947 has high oncolytic efficacy in ovarian cancer ([@bib27]), by a mechanism independent of classical apoptosis ([@bib3]), but involving abrogation of multiple cell cycle checkpoints ([@bib9]).

Clinical trials with the adenovirus *dl*1520 (Onyx-015) suggested that combinations with chemotherapy are effective ([@bib16]). Paclitaxel can synergize with oncolytic adenoviruses in various tumor models ([@bib1]; [@bib7]). Suggested mechanisms include increased E1A ([@bib1]) and cell surface receptor expression ([@bib36]). However, the interactions between adenoviruses and paclitaxel remain unclear and understanding them will facilitate future trial design.

Adenoviruses induce microtubule alterations after infection ([@bib39]), including early stabilization ([@bib41]). The importance of the microtubule network for adenovirus entry and nuclear translocation is well-characterized. After internalization, the viral capsid interacts with the motor protein dynein and travels with net movement toward the nucleus in a microtubule-dependent manner ([@bib24]). However, little is known about microtubules in adenoviral exit. Exit has been associated with the collapse and cleavage of the vimentin and cytokeratin networks ([@bib4]; [@bib43]) and E3 11.6 (Adenovirus Death Protein) may be important in very late cell lysis ([@bib40]). However, virus can be detected in the supernatant long before cell lysis, suggesting a pathway of continuous release.

Here, we have investigated how paclitaxel synergizes with *dl*922-947 in ovarian cancer and whether changes in microtubules influence this. We describe three novel findings. Firstly, *dl*922-947 induces an abnormal microtubule network and an increase in microtubule stability independently of paclitaxel. Secondly, we describe a role for microtubules in non-lytic virus exit. Thirdly, we demonstrate that paclitaxel synergizes with *dl*922-947 by deregulating the activity of mitosis-promoting factors, leading to mitotic slippage, multinucleation and apoptosis induction.

Results
=======

The oncolytic adenovirus *dl*922-947 synergizes with low-dose paclitaxel in ovarian cancer
------------------------------------------------------------------------------------------

*dl*922-947 has significant activity against IGROV1 xenografts ([@bib27]), but little against A2780CP ([@bib45]). To test whether paclitaxel can augment *dl*922-947 activity *in vivo*, we used two different regimes. In the first, mice bearing intraperitoneal (i.p.) A2780CP-luciferase xenografts received three weekly doses of i.p. *dl*922-947 and/or 20 mg/kg paclitaxel. Combination treatments were separated by 24 h, with virus injected first. In this highly aggressive model, mice in the vehicle group developed disseminated disease within peritoneum and pelvis by day 24. As before, treatment with either *dl*922-947 or paclitaxel alone was ineffective. However, when combined with paclitaxel, a significant reduction in tumor burden was seen at day 38 compared with paclitaxel alone ([Figure 1a](#fig1){ref-type="fig"}, left; *P*=0.046).

A second *in vivo* regime was tested in which paclitaxel was fractionated into four daily doses of 5 mg/kg commencing 24 h after *dl*922-947. As before, tumors in mice receiving *dl*922-947 grew exponentially ([Figure 1a](#fig1){ref-type="fig"}, right). Fractionation of the paclitaxel appeared to improve its activity compared with *dl*922-947 alone, although differences in radiance did not reach statistical significance (*P*=0.06--0.09). However, a significant reduction in tumor growth was still observed in the group receiving *dl*922-947 plus paclitaxel (*P*=0.044). When the last mouse in the paclitaxel group was killed because of tumor burden (day 56), three mice in the combination group remained alive with no tumors detectable by bioluminescence or necropsy. Livers from experiment 1 were examined ([Figure 1c](#fig1){ref-type="fig"}). In the vehicle group, livers were healthy, whereas those from the paclitaxel group showed necrosis and hemorrhage. We observed hepatotoxicity in some *dl*922-947-treated mice, as previously ([@bib27]), with thickening of the capsule and inflammatory cell infiltration; this was increased in the combination group.

To model this synergy *in vitro,* we infected A2780CP cells and added low-dose (3 n) paclitaxel up to 72 h post-infection (p.i.). Paclitaxel increased the efficacy of *dl*922-947, with the greatest effect seen when chemotherapy was added 24 h p.i. ([Figure 1d](#fig1){ref-type="fig"}, left). Combination treatment also led to a marked reduction in EC50 in IGROV1 cells, using two doses of paclitaxel ([Figure 1d](#fig1){ref-type="fig"}, right), confirming that the effect is not cell-specific. The synergy was unrelated to primary adenovirus infection as low-dose paclitaxel had no effect on cell surface CAR expression in either cell line and did not increase infectivity by Ad5 vectors, whether given before or after virus (data not shown).

Use of fluorescent adenovirus to assess replication and virus exit
------------------------------------------------------------------

We hypothesized that paclitaxel/*dl*922-947 synergy may result from alterations to microtubules. To visualize these, we constructed a derivative of *dl*922-947, *dl*CR2-pIX-dsRed, in which the minor capsid protein pIX is fused to the fluorescent protein dsRed, as others have done with green fluorescent protein (GFP) ([@bib22]; [@bib30]). The modified viral capsid did not reduce cytotoxic efficacy (Supplementary Figure 1) and *dl*CR2-pIX-dsRed could be detected in proximity to, and within, the nucleus of IGROV1 cells as early as 1 h post-infection ([Figure 2a](#fig2){ref-type="fig"}, left). We also detected viral particles being released from cells 48 h p.i., showing that *dl*CR2-pIX-dsRed is a useful tool to study adenovirus intracellular trafficking and exit. We detected a time-dependent increase in emitted fluorescence from *dl*CR2-pIX-dsRed-infected cells ([Figure 2b](#fig2){ref-type="fig"}), which correlated closely with intracellular virion titer ([Figure 2c](#fig2){ref-type="fig"}; *r*^2^=0.8999). Thus, *dl*CR2-pIX-dsRed can also be used for indirect measurement of intracellular viral replication.

Adenovirus induces rearrangements and stabilization of the microtubule cytoskeleton in ovarian cancer cells
-----------------------------------------------------------------------------------------------------------

To investigate host-cell microtubules, A2780CP cells were analyzed by confocal microscopy 48 h after *dl*CR2-pIX-dsRed infection ([Figure 3a](#fig3){ref-type="fig"}). Microtubules were rearranged in a circular formation compared with the radial organization in uninfected cells. Strikingly, abnormal microtubule organization was also seen in IGROV1 cells, with clustered or aggregated structures ([Figure 3b](#fig3){ref-type="fig"}). We used three methods to investigate the effects of combined virus and paclitaxel. First, *dl*CR2-pIX-dsRed-infected cells were stained for acetylated tubulin, a marker of microtubule stability ([@bib42]) ([Figure 4a](#fig4){ref-type="fig"}). Infected cells contained large amounts of acetylated tubulin organized in a ring, whereas acetylated microtubule fibers were dispersed in the cytoplasm in control cells. Second, immunoblots also demonstrated increased tubulin acetylation after adenovirus infection ([Figure 4b](#fig4){ref-type="fig"} and Supplementary Figure 2), but the addition of low-dose paclitaxel could not stabilize microtubules further. Finally, in a microtubule polymerization assay, the amount of polymerized tubulin increased from 16 to 34% following *dl*922-947 (multiplicity of infection (MOI) 10) infection. Low-dose paclitaxel alone increased polymerization (30%) but, at MOI 10, there was no significant increase in the presence of both virus and drug ([Figure 4c](#fig4){ref-type="fig"}). Modulating acetylated tubulin levels by HDAC6 inhibition, however, did not affect viral efficacy (Supplementary Figure 3). Taken together, these data suggest that tubulin is stabilized at later time points after adenovirus infection but that low-dose paclitaxel does not synergize with *dl*922-947 by augmenting this tubulin stabilization.

Microtubules are important for adenovirus exit
----------------------------------------------

We next determined whether paclitaxel and the microtubule network affected viral protein synthesis, replication and exit from cells. There were only minor changes in viral protein expression in the presence of three microtubule-targeting drugs, in particular no increase in E1A levels ([Figure 5a](#fig5){ref-type="fig"}). No change in intracellular viral replication in the presence of paclitaxel or nocodazole was seen ([Figure 5b](#fig5){ref-type="fig"}). However, there was a significant decrease in virus release with 300 n nocodazole: 5.3 × 10^6^ p.f.u./ml without nocodazole vs 2.1 × 10^5^ p.f.u./ml with nocodazole, *P*=0.005. Paclitaxel, by contrast, had no effect on release ([Figure 5b](#fig5){ref-type="fig"}). Nocodazole (300 n) induces a strong G2/M arrest in A2780CP cells (Supplementary Figure 4). To distinguish whether adenoviral release depends upon mitotic progression or functional microtubules, *dl*922-947-infected cells were treated with dimethylenastron, an inhibitor of the mitotic motor protein Eg5, which induces mitotic arrest without targeting the microtubule network ([@bib14]). As before, nocodazole significantly decreased the amount of virus released without altering intracellular replication (*P*⩽0.01). By contrast, dimethylenastron, which induced a similar degree of cell cycle arrest as nocodazole (Supplementary Figure 4), had no effect upon virus release, despite a small but significant increase in intracellular *dl*922-947 replication (1.3 × 10^7^ vs 2.4 × 10^7^ p.f.u./ml, *P*=0.016; [Figure 5c)](#fig5){ref-type="fig"}. To ensure that the microtubule-targeting drugs were not altering virus release by affecting cell lysis, a lactate dehydrogenase release assay was performed. Lactate dehydrogenase release was low in *dl*922-947-infected cells, and the combination of virus and microtubule-targeting drugs did not increase cell lysis further (Supplementary Figure 5A). In addition, there was an inverse correlation between cell lysis and cell viability in both A2780CP and IGROV1 cells infected with either *dl*922-947 or *dl*309 (Supplementary Figure 5B). This indicated that virus is released from intact, viable cells through a microtubule-dependent pathway of non-lytic virus exit. However, paclitaxel does not utilize this pathway to synergize with adenovirus. This was reinforced by RNAi-mediated downregulation of CLASP proteins, which will reduce microtubule stability without causing depolymerization, and had minimal effects on virus release (Supplementary Figure 6).

Low-dose paclitaxel deregulates mitotic progression, associated with mitotic slippage, multinucleation and apoptosis
--------------------------------------------------------------------------------------------------------------------

We then investigated cell cycle changes: we have previously shown that *dl*922-947 can override multiple cell cycle checkpoints ([@bib9]), whereas low-dose paclitaxel causes aberrant mitosis and mitotic slippage rather than G2/M arrest ([@bib6]; [@bib12]). Cells were first analyzed by immunofluorescence, revealing a population of multinucleated cells and cells with multipolar spindles following treatment with paclitaxel alone or in combination ([Figure 6a](#fig6){ref-type="fig"}). However, there was no significant change in the mitotic index after *dl*922-947 infection or combination treatment, indicating that cells do not accumulate in mitosis (Supplementary Figure 7).

By flow cytometry, 24 h of low-dose paclitaxel in A2780CP cells induced an increase in the sub-G1 population only (0.3% vs 10.4%) with no G2/M arrest. *dl*922-947 alone produced a significant reduction in G1 (54.1% vs 42.9%, *P*=0.008), with a small but significant increase in \>4N population (2.5 vs 10.8%). Combination treatment resulted in a profile with combined features: 9.8% sub-G1 and 13.3% \>4N ([Figure 6b](#fig6){ref-type="fig"}, upper panel), suggesting aberrant mitotic progression with apoptosis induction. Time-lapse microscopy of A2780CP-GFP-tubulin cells showed that paclitaxel, with or without *dl*922-947, increased the percentage of cells dividing with multipolar spindles compared with *dl*922-947 or mock infection ([Figure 6b](#fig6){ref-type="fig"}, lower panel, Supplementary Figure 8). Thus, paclitaxel-treated cells and cells receiving combination treatment slip through mitosis in the presence of multipolar spindles to generate multiple and/or multinucleated daughter cells.

We next determined the expression and activity of the mitosis-promoting complex cyclin B1/cdk1 ([Figure 6c](#fig6){ref-type="fig"}, quantified in Supplementary Figure 9). There was an increase in cyclin B1 levels 48 h following *dl*922-947 infection. Surprisingly, cyclin B1 levels, the degradation of which is normally a prerequisite of mitotic exit ([@bib34]), stayed high following paclitaxel treatment, suggesting either that cells can progress through mitosis in the presence of high levels of cyclin B1 or that degradation is slow or delayed. Levels of phospho-histone H1, a marker of cyclin B1/cdk1 activity, rose after paclitaxel or *dl*922-947 alone, and increased further when the two were combined. Thus, both *dl*922-947 and low-dose paclitaxel activate proteins involved in mitotic progression, confirming our previous finding that *dl*922-947 overrides multiple cell cycle checkpoints ([@bib9]). This suggests again that paclitaxel/*dl*922-947 synergy results from mitotic slippage and multinucleation.

Aberrant mitosis can trigger an apoptotic response ([@bib11]). However, we have shown that oncolytic adenoviruses do not induce classical apoptosis ([@bib3]). To determine the effects of combination treatment, we analyzed cells for classical apoptosis markers ([Figure 6d](#fig6){ref-type="fig"}). As before, there was no increase in apoptosis in either A2780CP or IGROV1 following *dl*922-947 infection, whereas paclitaxel increased all markers in both cell lines. After combined treatment, high levels of activated caspase-3 and annexin-V positivity were seen again. Therefore, chemotherapy-induced apoptosis is dominant over the virus-induced death pathway when combining paclitaxel and *dl*922-947, although, interestingly, the presence of virus slightly reduced the effect when compared with paclitaxel alone.

Discussion
==========

One strategy to increase oncolytic virus gene therapy efficacy in clinical trials is to combine it with chemotherapy. Here, we show that paclitaxel synergizes with the oncolytic adenovirus *dl*922-947 both *in vitro* and *in vivo* in the aggressive ovarian cancer xenograft model A2780CP by a mechanism of mitotic slippage leading to apoptosis.

We first studied host-cell microtubules because paclitaxel is a microtubule-stabilizing drug and adenoviruses require microtubules for nuclear transport. In agreement with others ([@bib39]; [@bib41]), we demonstrate that adenovirus induces wholesale microtubule rearrangements and that microtubules are stabilized. We also show, for the first time, that microtubules are important for viral exit independently of cell lysis. However, modulating the stability of microtubules either by inhibition of HDAC6 or by downregulating CLASP1/2 does not alter oncolytic efficacy and viral exit, respectively. Thus, microtubules are important for non-lytic adenoviral exit, but their stabilization is not fundamental to the viral lifecycle. Nocodazole at high concentration has been shown to induce actin stress fibre formation and cell contraction ([@bib5]). Thus, the actin cytoskeleton may also have a role in non-lytic adenoviral exit. Further work is required to assess the contribution of the actin network in non-lytic adenoviral exit.

Microtubule stability and increased infectivity also could not explain the synergy between paclitaxel and *dl*922-947. At MOI 10, microtubules are already stable in infected cells and paclitaxel did not increase this further. At the nanomolar concentrations required for these studies, paclitaxel did not cause mitotic arrest but led to mitotic slippage, multipolar mitosis and multinucleation, resulting in apoptosis, in agreement with others ([@bib33]; [@bib6]; [@bib12]). The apoptotic effect of paclitaxel was retained when combined with *dl*922-947, although we have previously shown that ovarian cancer cells do not die through classical apoptosis on exposure to *dl*922-947 ([@bib3]). This will have implications for combination clinical trials in recurrent cancers, where multiple apoptosis abnormalities have been described ([@bib35]).

Similar to others ([@bib32]; [@bib8]), we have shown that adenoviruses can abrogate multiple cell cycle checkpoints ([@bib9]). Some adenoviral proteins can affect mitotic progression and induce apoptosis. Adenoviral E4orf4 interacts with the protein phosphatase 2A, thereby inactivating the anaphase-promoting complex and inducing apoptosis ([@bib38]; [@bib21]). In addition, it was recently shown that E4orf4 induces cell death by mitotic catastrophe ([@bib26]). Adenovirus E1A and infection with *dl*1520 have both been shown to increase Mad2 protein levels ([@bib18]; [@bib8]). E1A can also induce centrosome amplification ([@bib10]) and adenovirus death protein interacts with MAD2B ([@bib44]). Thus, cell cycle abrogation and mitotic catastrophe may have important roles in adenoviral-induced cell death. Work exploring the importance of the \>4N DNA population in adenovirus-infected cells is ongoing.

In our experiments, cyclin B1/cdk1 activity increased in a time-dependent manner in *dl*922-947-infected cells, indicating that cells are able to enter mitosis. The degradation of cyclin B1 is a prerequisite for mitotic exit and mitotic slippage (reviewed in [@bib34]). Cyclin B1 levels were relatively low in paclitaxel-treated cells. At the same time, there was a small increase in the number of mitotic cells, suggesting that cells do enter mitosis and cyclin B1 is possibly degraded as the cells slip through. To our surprise, cyclin B1 levels were high in the infected cells in the presence of paclitaxel. This supports our previous findings that *dl*922-947 can abrogate multiple cell cycle checkpoints ([@bib9]). The degradation of cyclin B1 might be inhibited or delayed in these cells, possibly mediated by inhibition of the APC by E4orf4. Further work assessing cyclin B1 degradation in single cells after infection would answer this question.

In summary, we have shown that paclitaxel synergizes with oncolytic adenovirus through a mechanism of mitotic slippage leading to multinucleation and apoptosis. Despite its mode of action as a microtubule-stabilizing drug, paclitaxel\'s effects on viruses occur independently of microtubule stabilization. Given the importance of aberrant mitosis to the biology of viruses, our results suggest that drugs that interfere with mitotic checkpoints, such as aurora kinase inhibitors, may also be able to augment the efficacy of adenoviruses and offer the possibilities of new clinical trials.

Materials and methods
=====================

Cell lines, viruses, chemicals and siRNA
----------------------------------------

A2780CP and IGROV1 cells were cultured in Dulbecco\'s modified Eagle\'s medium plus penicillin and streptomycin and 10% fetal calf serum (PAA Laboratories, Pasching, Austria). A2780CP-GFP tubulin single-cell clones were generated following transfection with pEGFP-Tub (Clontech Laboratories, Inc., Saint-Germain-en-Laye, France), G418 selection, cell sorting and growth in 96-well plates. *dl*922-947 is an Ad5 vector deleted in amino acids 122--129 of E1A-CR2 as well as E3B ([@bib17]). *dl*309 is the wild-type control of *dl*922-947, with full-length E1A and the same E3B deletion. The chemicals used in this study were paclitaxel and vincristine (chemotherapy pharmacy, St Bartholomew\'s Hospital, London), Nocodazole (Sigma, Poole, UK), MG132 (z-Leu-Leu-Leu-al) (Sigma), dimethylenastron (ALX-270-438-M001, Alexis Biochemicals, Nottingham, UK) and tubacin (a gift from Dr S Schreiber). CLASP siRNA sequences were based on published sequences ([@bib31]). CLASP1 siRNA: 5′-GCCATTATGCCAACTATCT-3′, CLASP2 siRNA: 5′-GTTCAGAAAGCCCTTGATG-3′. All oligos were purchased from Dharmacon. ON-TARGETplus Control Pool (D-001810-10-20, Dharmacon, Epsom, UK) was used as scrambled control. Cell survival was assessed by MTT assay as before ([@bib27]).

Generation of *dl*CR2-pIX-dsRed
-------------------------------

To generate *dl*CR2-pIX-dsRed, dsRed was fused to the minor capsid protein pIX separated by a FLAG epitope and recombined into the *dl*CR2 plasmid. To allow for recombination, left- and right-arm homology sequences were generated flanking the pIX sequence. The left-arm homology sequence encoding pIX was fused in frame with a FLAG epitope and monomeric dsRed into the pDsRed-Monomer-N1 plasmid (Clontech). To generate the left-arm homology sequence, cDNA encoding the *pIX* gene between Ad5 nt 3609--4028 was amplified using wild-type Ad5 as template. Sense and anti-sense primers were flanked by *Age*I enzyme restriction sequences. A FLAG epitope sequence was incorporated in the antisense primer. Sense: 5′-[ACCGGT]{.ul}**ATACCTGTGTGGAAGCCTGGA**-3′. Underlined nucleotides denotes the *Age*I site, and nucleotides in bold correspond to Ad5 nt 2824--2844. Anti-sense: 5′-[ACCGGT]{.ul}GC**GTACTTCTTCTTCTTGTAGTC**AACCGCATTGGGAGGGGAGGAAGCCTTCA-3′. Underlined nucleotides represent *Age*I, and nucleotides in bold the FLAG epitope. Ad5 nt 4000--4028 are shown after the FLAG epitope sequence. The PCR product was subcloned into the pCRII-TOPOVector (Invitrogen, Paisley, UK). The pIX fragment was cloned into pDsRed-Monomer-N1 to generate the left-arm homology pIX-FLAG-dsRed cassette. A right-arm homology sequence starting immediately after the pIX stop codon (nt 4032) was generated using wild-type Ad5 as template with the following primers. Sense: 5′-[AAGCTT]{.ul}**AACATAAATAAAAAACCAGACTCTGTTTGG**. Underlined nucleotides represent *Hin*dIII site; nucleotides in bold Ad5 nt 4032--4061. Anti-sense: 5′-[AAGCTT]{.ul}*TGACCCAGACTACGCTGACG*. Underlined nucleotides represent *Hin*dIII; nucleotides in italics Ad5 nt 5339--5320. The fragment was subcloned into pCRII-TOPOVector, and cloned into the right arm of the shuttle plasmid pSuperShuttle. A full description of pSuperShuttle is found elsewhere (Oberg *et al.*, in preparation). The left-arm homology pIX-FLAG-dsRed cassette was excised from pDsRed-Monomer-N1 as a *Kpn*I/*Not*I fragment and ligated into the left-arm of pSuperShuttle. pSuperShuttle -pIX-FLAG-dsRed was then linearized to generate a fragment of the left and right homology arms. This fragment was recombined with the *dl*CR2 plasmid ([@bib25]) in BJ5193 *Escherichia coli*. Positive recombinants were amplified and the final product transfected into 293 cells for virion production. Viruses were purified on double CsCl gradients.

Immunofluorescence
------------------

Cells were grown on poly\--lysine (Sigma) coated coverslips and fixed in 100% methanol for 5 min at −20 °C followed by four washes in phosphate-buffered saline (PBS). Cells were then blocked in 1.5% bovine serum albumin and PBS-Tween (0.05% Tween-20 in PBS) for 30 min at room temperature. Cells were washed once in PBS followed by incubation with primary antibodies for 1 h at room temperature, washed four times in PBS-Tween and incubated with secondary antibodies for 1 h at room temperature. Coverslips were washed followed by staining with 4′,6-diamidino-2-phenylindole (DAPI, Invitrogen) for 1 min. Cells were washed twice in PBS and mounted onto glass slides.

Western blotting
----------------

Cells were lysed in 200 μl lysis buffer (150 m NaCl, 50 m Tris Base, 0.05% SDS, 1% Triton X-100, with Complete Protease inhibitor cocktail tablets (Roche Diagnostics GmbH), pH 8) followed by sonication on ice. Whole-cell lysate (20--30 μg) was resolved on SDS-polyacrylamide gels, and transferred to nitrocellulose membranes by semi-dry transfer (BioRad, Hemel Hempstead, UK). Unless otherwise stated, membranes were blocked in 4% non-fat milk in PBS-Tween (0.1%), followed by overnight incubation with primary antibodies. Proteins were detected by enhanced chemiluminescence (Amersham). Cyclin B1 was detected by blocking membranes in 3% bovine serum albumin-PBS/Tween for 1 h at room temperature. CLASP proteins were resolved on 6% SDS--PAGE gels and transferred onto nitrocellulose membranes by wet transfer. Membranes were blocked in 2% bovine serum albumin and 0.05% PBS-Tween for 2 h at room temperature followed by incubation with CLASP antibodies overnight at room temperature.

Histone purification
--------------------

Cells were resuspended in 0.5% Triton X-100/PBS supplemented with protease and phosphatase inhibitors (Complete Protease inhibitor cocktail tablets and PhosSTOP Phosphatase Inhibitor Cocktail Tablets (Roche Diagnostics GmbH)) followed by incubation on ice for 10 min. Cells were centrifuged at 2000 r.p.m., for 10 min at 4 °C. Pellets were resuspended in 0.5 volume 0.5% Triton X-100/PBS and centrifuged as above. The remaining pellet was resuspended in 0.1  HCl and histones extracted overnight at 4 °C. Samples were centrifuged and supernatant collected. In all, 20 μg of extracted histones was analyzed on SDS--PAGE gel.

Antibodies
----------

The following antibodies were used for immunoblots: CLASP1 (\#2292) and CLASP2 (\#2358) antibodies were a kind gift from Dr N. Galjart, ([@bib2]; [@bib31]). Anti-α-tubulin (Abcam, Cambridge, UK), anti-acetylated-tubulin (Sigma), anti-Adenovirus-2/5 E1A (Santa Cruz, Heidelberg, Germany), anti-Adenovirus5 (Abcam), anti-Ku70 (Santa Cruz), anti-cyclin B1 (BD Pharmingen, Oxford, UK), anti-Mad2L1 (Abcam), anti-phospho-histone H1, (Abcam). Primary antibodies for immunofluorescence were anti-β-tubulin (Sigma) and anti-acetylated-tubulin (Sigma).

Tubulin polymerization assay
----------------------------

Tubulin polymerization assays were based on those previously described ([@bib15]). Floating cells were collected by centrifugation and all cells were then lysed in 200 μl hypotonic buffer (37 °C in the dark). The buffer was complemented with Complete Protease inhibitor tablets (Roche, Welwyn Garden City, UK). Lysate was centrifuged (14 000 r.p.m., room temperature 10 min) and the supernatant (soluble fraction, S) removed. The insoluble fraction (P) was resuspended in 200 μl hypotonic buffer. Both samples were incubated on ice, sonicated and mixed with 200 μl 2 × SDS loading buffer. 20 μl was separated on SDS--PAGE gels.

Intracellular viral replication assay using *dl*CR2-pIX-dsRed
-------------------------------------------------------------

These experiments used phenol red medium. 3 × 10^5^ cells were seeded overnight in six-well plates, then washed in serum-free, phenol red-free medium. Cells were infected with *dl*CR2-pIX-dsRed (MOI 1 p.f.u./cell) in 500 μl serum-free medium without phenol red for 3 h and refed with phenol red-free medium+2% fetal calf serum. The fluorescence was measured for 1 s using a Victor^3^ TM1420 multilabel counter (Perkin Elmer, Buckinghamshire, UK) with 544/15 nm excitation and 620/8 nm emission filters. Fluorescent averages were calculated and values for untreated cells subtracted from those of infected cells to reveal the net mean fluorescence. After each scan, cells were scraped in medium and centrifuged (5 min, 1500 r.p.m.), washed in 0.1  Tris, pH 8, and re-pelleted. Cells were resuspended in 0.1  Tris pH8 followed by three rounds of freeze thawing (liquid N~2~/37 °C). Virus was titered on JH293 cells. For viral exit assays, medium was collected from virus-infected cells and centrifuged for 5 min at 4000 r.p.m. The supernatant was titered.

Flow cytometry
--------------

Cells were fixed in ice-cold 70% ethanol and fixed for \>30 min at 4 °C followed by centrifugation at 1500 r.p.m. for 5 min. Pellets were washed in PBS, resuspended in 50 μl of 100 μg/ml of RibonucleaseA, (R-4642) (Sigma) in PBS and incubated at 37 °C for 15 min. Cells were then stained with propidium iodide (Invitrogen, Molecular Probes, Paisley, UK) to a final concentration of 50 μg/ml and analyzed by flow cytometry (BD FACS Calibur, Becton Dickinson, Oxford, UK).

Microscopy and live-cell imaging
--------------------------------

Hematoxylin and eosin slides were analyzed with an Axiophot microscope (Zeiss, Jena, Germany) coupled to a Nikon Digital Camera, DXM1200. Images were acquired with × 5 or × 20 Plan-Neofluar objectives (Zeiss). Confocal analysis was performed with an inverted Zeiss LSM 510 META laser-scanning microscope with a Plan-Apochromat × 63/1.4 oil objective. DAPI was detected with a 405-nm laser, Alexa Fluor 488 with a 488-nm laser and dsRed with a 543-nm laser. Images were acquired in the *x*, *y*, *z* direction, with a line average of 4 except for [Figure 1b](#fig1){ref-type="fig"} and Supplementary Figure 1, where images were acquired in the *x*, *y* direction with a line average of 8. Z-sections were acquired at optimum interval levels with sections of 0.36--0.43 μm. Microscope settings were kept the same for all images in each experiment. Maximal intensity Z-projections were assembled with the LSM5 Image browser software.

A2780CP GFP-tubulin cells were grown on poly\--lysine-coated glass bottom culture dishes (MatTek Corporation, Ashland, MA, USA). The medium was changed to Leibovitz\'s L-15 medium without phenol red (21083, GIBCO, Invitrogen) before imaging. Images were acquired in a closed system at 37 °C with a motorized, epi-fluorescence, inverted Zeiss Axiovert 200M microscope coupled to a Hamamatsu Orca 12 bit, 1280 × 1280 pixel CCD camera. To detect GFP-tubulin, images were acquired every 30 min over 24 h with an LD-A-plan × 20 objective (Zeiss), exposure time of 1.5 s and gain of 100. Autoexposure was performed for every third image throughout. Films were assembled with the Simple PCI software (Digital Pixel) and processed in ImageJ.

*In vivo* experiments
---------------------

Experiments were carried out under suitable UK Home Office personal and project license authority, using 6--8-week-old female BALB/c *nu*/*nu* mice (Harlan, Huntington, UK). In experiment 1, 3 × 10^6^ A2780CP-luciferase cells were injected i.p. on day 1. Mice received three weekly doses of *dl*922-947 (5 × 10^9^ particles) and/or paclitaxel (20 mg/kg) starting at day 5. Combination treatments were separated by 24 h, with virus injected first. In experiment 2, paclitaxel was fractionated into four daily doses of 5 mg/kg on days 5--8 commencing 24 h after *dl*922-947. All mice were assessed daily for weight, general health and accumulation of ascites and were killed according to UK Home Office guidelines. At post-mortem, livers were harvested, fixed in 10% formaldehyde (w/v) and 4 μm sections stained with hematoxylin and eosin.

Mice were anesthetized (2% isofluorane by inhalation) and injected i.p. with 125 mg/kg -luciferin (Calliper Life Sciences, Runcorn, UK). Five minutes later, although still under anesthetic, they were placed in a light-tight chamber on a warmed stage (37 °C) and light emission from a defined region of interest on a ventral surface was imaged on a Xenogen IVIS 100 Imaging System (Alameda, CA, USA). Data were analyzed using Living Image software (also Xenogen) and are presented as mean radiance (photons/s/cm^2^/sr).

Apoptosis assays
----------------

Cells were incubated with 40 n tetramethylrhodamine ethyl ester perchlorate (Invitrogen) for 10 min, washed in PBS and resuspended with Annexin V-Alexa 647 conjugate (2.5 μg/ml) for 15 min. DAPI (1 μg/ml) was then added. For caspase activation analysis, cells were incubated for 60 min with 10 μ PhiPhiLux-G~1~D~2~ substrate (OncoImmunin Inc, Gaithersburg, MD, USA) before DAPI addition, then analyzed on a FACS LSRII (Becton Dickinson) and the data processed using FlowJo software (Tree Star, Ashland, OR, USA).

Cell lysis assay
----------------

Lactate dehydrogenase activity in the medium was measured with the Cytotoxicity Detection Kit (lactate dehydrogenase) (Roche Applied Science). The absorbance values were read at 490 and 630 nm with a Victor^3^ TM1420 multilabel counter (Perkin Elmer). The net absorbance was calculated by subtracting the average reference 630 nm values from the average 490 nm readings.

Statistics
----------

All statistical analyses were generated with GraphPad Prism 5.00 (San Diego, CA, USA). All statistical analyses are unpaired, two-tailed, Student\'s *t*-test unless otherwise stated.
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![*dl*922-947 synergizes with paclitaxel *in vitro* and *in vivo*. (**a**) Female BALB C nude mice (5 mice/group) were injected i.p. with 3 × 10^6^ A2780CP luciferase cells on day 1 followed by paclitaxel (20 mg/kg) or *dl*922-947 (5 × 10^9^ particles) treatment on day 5. The combination group was treated with paclitaxel on day 6. Treatments were repeated weekly for 3 weeks (left). *dl*922-947 was given weekly on days 4, 11 and 18. \**P*=0.046, one-tailed, unpaired Student\'s *t*-test. Low-dose paclitaxel (5 mg/kg) was administered i.p. daily for 4 days starting on days 5, 12 and 19 (right panel). \**P*=0.044 (one-tailed, unpaired Student\'s *t*-test). (**b**) Day 24 bioluminescence images from (**a**) (left). (**c**) Histopathology of livers from mice in (**a**). (Left) 4 μm liver sections were stained with H&E. (**d**) A2780CP cells were infected with *dl*922-947 and treated with 3 n paclitaxel up to 72 h post-infection (p.i.; left). Cell survival was analyzed by MTT assay. Calculated EC50 values are shown (p.f.u./cell). IGROV1 cells were infected as above and treated with 1 or 10 n paclitaxel 24 hours p.i. (right).](onc2010335f1){#fig1}

![Use of *dl*CR2-pIX-dsRed to monitor infection, virus replication and exit. (**a**) Visualization of viral entry and exit. IGROV1 cells were infected with *dl*CR2-pIX-dsRed on ice for 1 h (0 h p.i. timepoint). Cells were warmed to 37 °C for 1 h, stained with β-tubulin, DAPI and subjected to confocal analysis (left). Scale bar=10 μm. A2780CP cells were infected with *dl*CR2-pIX-dsRed (MOI 1) and analyzed as above 48 h p.i. (right). (**b**) A2780CP cells were infected with *dl*CR2-pIX-dsRed (MOI 1). The emitted fluorescence was measured with a plate reader in 12 h intervals up to 72 h p.i. (**c**) Scatter-plot analysis of data in B combined with intracellular viral replication as p.f.u./ml showing a correlation between fluorescence and intracellular viral replication (*r*^2^ value=0.8999).](onc2010335f2){#fig2}

![Adenovirus induces rearrangements of the microtubule network in ovarian cancer cells. (**a**) A2780CP cells were infected with *dl*CR2-pIX-dsRed (MOI 0.1), fixed in ice-cold methanol 48 h p.i., stained with antibodies against β-tubulin and counterstained with DAPI. Cells were analyzed by confocal microscopy. Scale bar=10 μm. (**b**) IGROV1 cells were infected on ice for 1 h. Unbound particles were washed off and the infection continued at 37 °C. Cells were fixed 72 h post-infection, stained and analyzed as in (**a**). Scale bar=20 μm.](onc2010335f3){#fig3}

![Microtubules are stable late after adenovirus infection. (**a**) A2780CP cell were infected with *dl*CR2-pIX-dsRed (MOI 1). Cells were fixed in methanol and stained with antibodies against acetylated-tubulin. *dl*CR2-pIX-dsRed was detected in the dsRed channel. Scale bar=10 μm. (**b**) IGROV1 cells were infected with *dl*922-947 (MOI 1 or 10) and treated with paclitaxel or nocodazole 24 h p.i. Protein bands on membranes were quantified on a phosphoimager (right). Ratios of acetylated tubulin/α-tubulin normalized to control cells are shown. Bars represent mean±s.e.m. (**c**) Microtubule polymerization assay. Soluble and insoluble microtubule fractions from *dl*922-947- and paclitaxel-treated cells were separated by centrifugation and analyzed by immunoblotting (left). Percentage polymerized tubulin was quantified according to the formula presented (right). Bars represent mean±s.e.m.](onc2010335f4){#fig4}

![Microtubules are important for non-lytic adenoviral exit. (**a**) The effect of microtubule-targeting drugs on viral protein expression. Cells were infected with *dl*922-947 (MOI 1) and treated with microtubule-targeting drugs 24 h p.i. Whole cell extracts were resolved on SDS--PAGE gels and immunoblotted with E1A and Ad5 antibodies 48 h p.i (left). Viral protein levels were quantified on a phosphoimager. Ratios of E1A, hexon or penton to Ku70 normalized to *dl*922-947-infected cells (MOI 1) are shown (right). (**b**) A2780CP cells were infected with *dl*CR2-pIX-dsRed (MOI 1) and treated as in (**a**). Intracellular viral replication was assessed by fluorescence assay 48 h p.i. (left). Supernatants were collected and assayed for released infectious viral particles by TCID50 assay (right). (**c**) Intracellular viral replication and viral exit assays. A2780CP cells were infected with *dl*922-947 (MOI 10) and treated with nocodazole (300 n) or dimethylenastron (1 μ) 24 h p.i. Intracellular (left) and released (right) virus was titered on JH293 cells as in (**b**). \**P⩽*0.05. \*\**P⩽*0.01.](onc2010335f5){#fig5}

![*dl*922-947 in combination with low-dose paclitaxel leads to mitotic defects, spindle checkpoint override and apoptosis in ovarian cancer cells. (**a**) A2780CP cells were infected with *dl*922-947 (MOI 10) and treated with 10 n paclitaxel 24 h later. Cells were fixed in methanol 48 h p.i. and stained for β-tubulin and DAPI. Scale bar=20 μm. Arrows denote micronucleated cells (left). Mitotic cells were analyzed with a 63 × objective and a zoom of 3 (right panel). Scale bar=10 μm. The number of micronucleated cells was counted. Data represent mean±s.d. from triplicate slides. \>200 cells were counted per slide (bottom left). (**b**) A2780CP cells were infected with *dl*922-947 (MOI 10) and treated with paclitaxel 24 h p.i. Cells were fixed and stained with propidium iodide and analyzed by flow cytometry (top). A2780CP GFP-tubulin cells were grown on poly\--lysine-coated coverslips and infected with *dl*922-947 (MOI 10). Cells were treated with 10 n paclitaxel 24 hours p.i. and analyzed by timelapse microscopy. Images were acquired every 30 min for \>20 h. The number of mitotic cells dividing with either bipolar or multipolar spindles was quantified. N represents the number of mitotic cells counted for each condition (bottom). (**c**) Immunoblot analysis of mitosis-regulating proteins in A2780CP cells. Cells were infected and treated with paclitaxel as in **a**. Proteins were extracted up to 72 h p.i. and analyzed for expression of cyclin B1 and phosphorylated histone H1. Nocodazole-treated cells (N) (300 n) were included as a positive control for cyclin B1/cdk1 activity. (**d**) Cells were infected with *dl*922-947 (V) followed by paclitaxel (P) treatment at 1 and 10 n 24 h p.i. 48 h p.i., cells were analyzed for the apoptosis markers Annexin-V, activated caspase-3 and TMRE staining by FACS.](onc2010335f6){#fig6}
